 Lines gained. Lives changed.
For US Healthcare Professionals Only
|
|||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||
INDICATIONLUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.IMPORTANT SAFETY INFORMATIONLUCENTIS is contraindicated in patients with ocular or periocular infections.Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis and retinal detachment. Proper aseptic injection technique should always be utilized when administering LUCENTIS. Patients should be monitored during the week following the injection to permit early treatment, should an infection occur. Increases in intraocular pressure (IOP) have been noted within 60 minutes of intravitreal injection. IOP and perfusion of the optic nerve head should be monitored and managed appropriately. Although there was a low rate (<4%) of arterial thromboembolic events (ATEs) observed in LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of inhibitors of VEGF. Serious adverse events related to the injection procedure occurring in <0.1% of intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract. Other serious ocular events occurring in <2% of patients included intraocular inflammation with or without hypersensitivity and increased IOP. In clinical trials, most common ocular side effects included conjunctival hemorrhage, eye pain, and vitreous floaters. Most common nonocular side effects included nasopharyngitis, headache, respiratory and urinary tract infections. LUCENTIS is for prescription use only. Individual results with LUCENTIS may vary. Please see LUCENTIS full Prescribing Information 
©2010 Genentech USA, Inc. All rights reserved.  |
|||||||||||||||||||||||||||
